Copper radiopharmaceuticals for theranostic applications

Ahmedova, Anife; Todorov, B.; Burdzhiev, Nikola; Goze, Christine

doi:10.1016/j.ejmech.2018.08.051

Cited by 50 publications

(50 citation statements)

References 175 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…67 Cu and 64 Cu) are excellent candidates for nano-theranostic applications due to the large variety of clinically relevant half-lives available (i.e. 0.16–62 h) and their clinically favourable emission characteristics ( β − , β + , or EC), which are suitable for both imaging and therapy 67,68 , as well as their compatibility for chelate-free labeling onto SPIO-core nanoparticles 20 . In addition, recent clinical studies 69–71 show great promise for 177 Lu and 213 Bi targeted radionuclide therapy.…”

Section: Discussionmentioning

confidence: 99%

Radio-enhancement effects by radiolabeled nanoparticles

Gholami

Maschmeyer

Kuncic

2019

Sci Rep

View full text Add to dashboard Cite

In cancer radiation therapy, dose enhancement by nanoparticles has to date been investigated only for external beam radiotherapy (EBRT). Here, we report on an in silico study of nanoparticle-enhanced radiation damage in the context of internal radionuclide therapy. We demonstrate the proof-of-principle that clinically relevant radiotherapeutic isotopes (i.e. 213Bi, 223Ra, 90Y, 177Lu, 67Cu, 64Cu and 89Zr) labeled to clinically relevant superparamagnetic iron oxide nanoparticles results in enhanced radiation damage effects localized to sub-micron scales. We find that radiation dose can be enhanced by up to 20%, vastly outperforming nanoparticle dose enhancement in conventional EBRT. Our results demonstrate that in addition to the favorable spectral characteristics of the isotopes and their proximity to the nanoparticles, clustering of the nanoparticles results in a nonlinear collective effect that amplifies nanoscale radiation damage effects by electron-mediated inter-nanoparticle interactions. In this way, optimal radio-enhancement is achieved when the inter-nanoparticle distance is less than the mean range of the secondary electrons. For the radioisotopes studied here, this corresponds to inter-nanoparticle distances <50 nm, with the strongest effects within 20 nm. The results of this study suggest that radiolabeled nanoparticles offer a novel and potentially highly effective platform for developing next-generation theranostic strategies for cancer medicine.

show abstract

Section: Discussionmentioning

confidence: 99%

Radio-enhancement effects by radiolabeled nanoparticles

Gholami

Maschmeyer

Kuncic

2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Indeed, by translating tumor-to-background ratios into potential absorbed radiation doses, this approach allows for improved optimal dosing for personalized medicine in the context of multimodality treatment strategies. Moreover, 64 Cu with the beta-emitting 67 Cu provides an interesting theranostic pair with easy switch between diagnostic and therapeutic applications [16,43]. Up until now, due to its difficult production process, research on 67 Cu is still restricted [16].…”

Section: Discussionmentioning

confidence: 99%

What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model

Bailly

Gouard

Guérard

et al. 2019

IJMS

View full text Add to dashboard Cite

Although positron emission tomography (PET) imaging with 18-Fluorodeoxyglucose (18F-FDG) is a promising technique in multiple myeloma (MM), the development of other radiopharmaceuticals seems relevant. CD138 is currently used as a standard marker for the identification of myeloma cells and could be used in phenotype tumor imaging. In this study, we used an anti-CD138 murine antibody (9E7.4) radiolabeled with copper-64 (64Cu) or zirconium-89 (89Zr) and compared them in a syngeneic mouse model to select the optimal tracers for MM PET imaging. Then, 9E7.4 was conjugated to TE2A-benzyl isothiocyanate (TE2A) and desferrioxamine (DFO) chelators for 64Cu and 89Zr labeling, respectively. 64Cu-TE2A-9E7.4 and 89Zr-DFO-9E7.4 antibodies were evaluated by PET imaging and biodistribution studies in C57BL/KaLwRij mice bearing either 5T33-MM subcutaneous tumors or bone lesions and were compared to 18F-FDG-PET imaging. In biodistribution and PET studies, 64Cu-TE2A-9E7.4 and 89Zr-DFO-9E7.4 displayed comparable good tumor uptake of subcutaneous tumors. On the bone lesions, PET imaging with 64Cu-TE2A-9E7.4 and 89Zr-DFO-9E7.4 showed higher uptake than with 18F-FDG-PET. Comparison of both 9E7.4 conjugates revealed higher nonspecific bone uptakes of 89Zr-DFO-9E7.4 than 64Cu-TE2A-9E7.4. Because of free 89Zr’s tropism for bone when using 89Zr-anti-CD138, 64Cu-anti-CD138 antibody had the most optimal tumor-to-nontarget tissue ratios for translation into humans as a specific new imaging radiopharmaceutical agent in MM.

show abstract

“…Ni(p,n) reaction [2-4, 17-19, 25, 30-44, 62-64] is the main method of production of 64 Cu, an isotope frequently used in positron emission tomography (PET) studies [5,18,20,30,64,65] and also applied in internal radiotherapy [20,44,66,67]. Another method of 64 Cu production using Ni targets is based on 64 Ni(d,2n) reaction [16,20,34,40,58]. Other PET radioisotopes which can be produced by means of nuclear reactions of nickel nuclei include 60 Cu, 61 Cu, 62 Cu, 55 Co and 57 Ni [5, 9-14, 16-22, 24-26, 28-30, 34, 35, 41, 45, 61, 65, 66, 68-70].…”

Section: Introductionmentioning

confidence: 99%

“…Ni(p,n) 60 Cu [18][19][20][21] nat Ni(α,x) 60 Cu [22,23] nat Ni (p,xn) 60 Cu [24] 61 Cu 3.34 h β + (62%) EC (38%)…”

Section: Introductionmentioning

confidence: 99%

Electrochemical deposition of nickel targets from aqueous electrolytes for medical radioisotope production in accelerators: a review

Mieszkowska

Grdeń

2021

J Solid State Electrochem

View full text Add to dashboard Cite

This paper reviews reported methods of the electrochemical deposition of nickel layers which are used as target materials for accelerator production of medical radioisotopes. The review focuses on the electrodeposition carried out from aqueous electrolytes. It describes the main challenges related to the preparation of suitable Ni target layers, such as work with limited amounts of expensive isotopically enriched nickel; electrodeposition of sufficiently thick, smooth and free of cracks layers; and recovery of unreacted Ni isotopes from the irradiated targets and from used electrolytic baths.

show abstract

Copper radiopharmaceuticals for theranostic applications

Cited by 50 publications

References 175 publications

Radio-enhancement effects by radiolabeled nanoparticles

Radio-enhancement effects by radiolabeled nanoparticles

What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model

Electrochemical deposition of nickel targets from aqueous electrolytes for medical radioisotope production in accelerators: a review

Contact Info

Product

Resources

About